Outcomes of Dual Mobility Bearings in Revision Total Hip Replacements.

Background Dual mobility bearings have gained attention in the prevention of instability in revision total hip replacement. This study aimed to evaluate the use of dual mobility bearings in revision total hip replacement. The primary outcome was the rate of dislocation. Secondary outcomes included the rate of re-operation for any reason, surgical complications, serious medical adverse events, and 90-day mortality rate. Methods A single-centre case series of 55 consecutive operations in 49 patients who underwent revision total hip replacement using dual mobility bearings with a minimum follow-up of three months was studied.  Results Early dislocation occurred in one case (2%), and there were no intra-prosthetic dislocations at a mean follow-up of 16 months. The rate of re-operation for any reason was 6/55 (11%) cases, and the post-operative infection rate was 2/55 (4%) cases. Serious medical adverse events occurred in 2/55 (4%) cases. The 90-day mortality rate was 1/55 (2%) cases. Two cases (2%) had cup abduction or anteversion angles outside of the safe zones although there were no dislocations in these patients. Conclusion This case series demonstrates a low dislocation rate in the early post-operative period for dual mobility bearings in revision total hip replacement. Dual mobility bearings show promise as an early low dislocation implant in revision total hip replacement. It remains to be determined whether dual mobility bearings are low-wear implants in the long term.

A review of the relatively complex mechanism of JS-K induced apoptosis in cancer cells.

Nitric oxide (NO) works as a signaling molecule, toxicant, and antioxidant in the body's physiological and pathological processes. JS-K is designed to be activated by glutathione-S-transferase (GST) and release NO in a sustained and controlled manner within the tumor cells. JS-K also promotes apoptosis in cancer cells through mitogen-activated protein kinase (MAPK) pathway, ubiquitin-proteasome pathway, cell factor ß-catenin/T (TCF) signaling pathway, and other mechanisms. In future studies, we should further develop new NO precursors, so that new drugs in the treatment of cancer can become more efficient, more accurate, and have less adverse reactions.